[{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Government of Canada","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Government of Canada"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Gilead Sciences"},{"orgOrder":0,"company":"Cyclica","sponsor":"Structural Genomics Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"DCAF1","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Structural Genomics Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Structural Genomics Consortium"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learning platform to assess commercially available libraries for potential binders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 11, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Structural Genomics Consortium

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AbCellera has expanded its collaboration with Gilead Sciences to include a multi-year, multi-target antibody discovery deal and access to AbCellera’s humanized mouse technology, the Trianni Mouse®.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 04, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 22, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Fund will expand AbCellera's efforts, as more than 500 specific human anti-SARS-CoV-2 antibodies have been established as part of a partnership with the Vaccine Research Center.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 05, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Government of Canada

                          Deal Size : $175.6 million

                          Deal Type : Funding

                          blank